A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE ASCENDING, SINGLE-DOSE STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF RAY121 IN HEALTHY VOLUNTEERS
This is an early study (Phase 1) looking into a new medicine called RAY121. It's designed for healthy volunteers, not people with a specific illness, to check its safety and how their bodies react to it. Scientists want to understand if RAY121 is well-tolerated, meaning it doesn't cause too many problems. They'll also find out how the medicine moves through the body, how long it stays, and if the body's immune system reacts to it. Some volunteers will get RAY121, and others a dummy medicine (placebo), without knowing which they're receiving. This helps make sure the results are accurate. This information is a crucial first step before testing the medicine in people who could benefit from it.
At a glance
What is this study about?
Imagine scientists are trying to build a new bridge. Before they let cars drive over it, they first test the materials and designs in a controlled environment to make sure they're strong and safe. This study, which is a 'Phase 1' clinical trial, is very similar. It's one of the first steps in testing a brand new medicine, called RAY121, which doctors hope might one day help people with conditions affecting their nervous system.
In this study, the main goal is simply to find out if RAY121 is safe for people. Since it's a new medicine, nobody knows yet how humans will react to it. Scientists will carefully give different amounts of RAY121 to a small group of healthy volunteers to see what effects it has. They'll be watching very closely for any side effects, even minor ones. This helps them find out what dose might be safe for future studies.
They also want to learn how the body handles RAY121. This includes understanding how the body absorbs the medicine, how it breaks it down, and how it gets rid of it. This information is vital because it helps doctors understand how often and how much of the medicine might need to be given if it proves to be helpful in treating illnesses later on. All of this groundwork is essential to ensure that any future studies involving people who are actually ill are as safe and well-informed as possible.
Key takeaways
- This is an early-stage study (Phase 1) of a new medicine called RAY121.
- The main goal is to check the medicine's safety and how the body handles it in healthy volunteers.
- You might receive the new medicine or a dummy medicine (placebo).
- It aims to help develop future treatments for nervous system conditions.
- You must be a healthy adult aged 18 or older to potentially participate.
Who may be eligible?
To join this study, you need to be a healthy adult aged 18 or older. Both men and women can take part. Being healthy means you don't have any serious ongoing medical conditions, especially those affecting your nervous system.
The research team will carry out a thorough check-up to make sure you're suitable. This usually involves reviewing your medical history, having a physical exam, and some basic tests like blood and urine checks. They want to make sure the medicine is tested in people who are generally well, so they can clearly see any effects from the medicine itself.
It's important to understand that even if you meet the age and health criteria, there might be other reasons you can't join. For example, certain medications you already take, or specific health details the doctors find during your screening, might mean the study isn't right for you. The medical team will explain all the requirements clearly.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you generally in good health?
- Do you have any conditions affecting your nerves or brain?
- Are you able to attend several study visits?
- Are you comfortable potentially receiving a placebo (dummy medicine)?
What does participation involve?
If you decide to take part, you'll first have a screening visit where doctors will check if you're suitable for the study. If you are, you'll be randomly assigned to either receive the study medicine (RAY121) or a dummy medicine (placebo) – neither you nor the study team will know which. You'll receive a single dose of the medicine.
After receiving the dose, you'll have several follow-up visits or phone calls. These visits allow the doctors to closely monitor your health, check for any side effects, and take blood or urine samples to see how the medicine is working in your body. The total amount of time you'll be involved in the study, from your first screening visit to your final follow-up, will be explained in detail by the study team, but it typically involves a few weeks or months.
Potential risks and benefits
Locations (1)
- —UnverifiedNetherlands
Common questions
What is a Phase 1 study?
It's an early-stage study, usually testing a new medicine in healthy people for the first time, to see if it's safe and how it behaves in the body.
Will I get the actual medicine (RAY121)?
You might get RAY121 or a placebo (dummy medicine). You won't know which, and neither will the study team, to keep the results fair.
What does 'nervous system disease' mean?
This refers to conditions affecting your brain, spinal cord, and nerves, like Parkinson's, MS, or Alzheimer's. RAY121 might be developed for such conditions in the future.
How long will I need to be involved?
The full duration will be explained by the study team, typically involving several visits over a few weeks or months after your single dose of medicine.
Do I have to take part?
No, taking part is completely voluntary. You can decide not to participate, or withdraw at any time, without it affecting your usual medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.